The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
IBS Treatment-Global Market Insights and Sales Trends 2024
Synopsis
Irritable bowel syndrome (IBS) is a common disorder that affects the digestive system. IBS is characterized by symptoms such as stomach cramps, bloating, diarrhea, and constipation, which impacts one’s everyday life. Although the cause of IBS is unknown, but few factors that cause IBS are severe infection, inflammation in the intestines, muscle contractions in the intestine, changes in bacteria in the gut, and abnormalities in the nerves.
The global IBS Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of IBS Treatment in various end use industries. The expanding demands from the Hospitals, Clinics and Research Laboratories,, are propelling IBS Treatment market. IBS-D, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the IBS-C segment is estimated at % CAGR for the next seven-year period.
Rising prevalence of gastrointestinal diseases and disorder, geriatric population, unhealthy diet, anxiety, depression, and changing lifestyle in Americas are the key drivers of the Americas IBS market. Moreover, strong clinical pipeline and government support is fuelling the market in this region. According to an updated report by the Anxiety and Depression Association of America, in 2017, the most common mental disorder was anxiety in the United States, affecting approximately 40 million adults over 18 years every year.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for IBS Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global IBS Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global IBS Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, IBS Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of IBS Treatment covered in this report include Allergan (Ireland), Sucampo Pharmaceuticals (U.S.), Ironwood Pharmaceuticals (U.S.), Astellas Pharma (Japan), Bausch Health, Abbott Laboratories (U.S.), Synergy Pharmaceuticals (U.S.), Ardelyx (U.S.) and Nestle (Switzerland), etc.
The global IBS Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Allergan (Ireland)
Sucampo Pharmaceuticals (U.S.)
Ironwood Pharmaceuticals (U.S.)
Astellas Pharma (Japan)
Bausch Health
Abbott Laboratories (U.S.)
Synergy Pharmaceuticals (U.S.)
Ardelyx (U.S.)
Nestle (Switzerland)
Sebela Pharmaceuticals (Ireland)
Probi (Sweden)
Alfasigma USA (Italy)
RedHill Biopharma (Israel)
AstraZeneca (U.K)
Ipsen (France)
Novartis (Switzerland)
Takeda Pharmaceutical Company (Japan)
Synthetic Biologics (U.S.)
Protagonist Therapeutics (U.S.)
Pfizer (U.S.)
Lexicon Pharmaceuticals (U.S.)
Innovate Biopharmaceuticals (U.S.)
Global IBS Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global IBS Treatment market, Segment by Type:
IBS-D
IBS-C
IBS-M
Global IBS Treatment market, by Application
Hospitals
Clinics
Research Laboratories
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of IBS Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Irritable bowel syndrome (IBS) is a common disorder that affects the digestive system. IBS is characterized by symptoms such as stomach cramps, bloating, diarrhea, and constipation, which impacts one’s everyday life. Although the cause of IBS is unknown, but few factors that cause IBS are severe infection, inflammation in the intestines, muscle contractions in the intestine, changes in bacteria in the gut, and abnormalities in the nerves.
The global IBS Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of IBS Treatment in various end use industries. The expanding demands from the Hospitals, Clinics and Research Laboratories,, are propelling IBS Treatment market. IBS-D, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the IBS-C segment is estimated at % CAGR for the next seven-year period.
Rising prevalence of gastrointestinal diseases and disorder, geriatric population, unhealthy diet, anxiety, depression, and changing lifestyle in Americas are the key drivers of the Americas IBS market. Moreover, strong clinical pipeline and government support is fuelling the market in this region. According to an updated report by the Anxiety and Depression Association of America, in 2017, the most common mental disorder was anxiety in the United States, affecting approximately 40 million adults over 18 years every year.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for IBS Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global IBS Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global IBS Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, IBS Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of IBS Treatment covered in this report include Allergan (Ireland), Sucampo Pharmaceuticals (U.S.), Ironwood Pharmaceuticals (U.S.), Astellas Pharma (Japan), Bausch Health, Abbott Laboratories (U.S.), Synergy Pharmaceuticals (U.S.), Ardelyx (U.S.) and Nestle (Switzerland), etc.
The global IBS Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Allergan (Ireland)
Sucampo Pharmaceuticals (U.S.)
Ironwood Pharmaceuticals (U.S.)
Astellas Pharma (Japan)
Bausch Health
Abbott Laboratories (U.S.)
Synergy Pharmaceuticals (U.S.)
Ardelyx (U.S.)
Nestle (Switzerland)
Sebela Pharmaceuticals (Ireland)
Probi (Sweden)
Alfasigma USA (Italy)
RedHill Biopharma (Israel)
AstraZeneca (U.K)
Ipsen (France)
Novartis (Switzerland)
Takeda Pharmaceutical Company (Japan)
Synthetic Biologics (U.S.)
Protagonist Therapeutics (U.S.)
Pfizer (U.S.)
Lexicon Pharmaceuticals (U.S.)
Innovate Biopharmaceuticals (U.S.)
Global IBS Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global IBS Treatment market, Segment by Type:
IBS-D
IBS-C
IBS-M
Global IBS Treatment market, by Application
Hospitals
Clinics
Research Laboratories
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of IBS Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of IBS Treatment
1.1 IBS Treatment Market Overview
1.1.1 IBS Treatment Product Scope
1.1.2 IBS Treatment Market Status and Outlook
1.2 Global IBS Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global IBS Treatment Market Size by Region (2018-2029)
1.4 Global IBS Treatment Historic Market Size by Region (2018-2023)
1.5 Global IBS Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, IBS Treatment Market Size (2018-2029)
1.6.1 North America IBS Treatment Market Size (2018-2029)
1.6.2 Europe IBS Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific IBS Treatment Market Size (2018-2029)
1.6.4 Latin America IBS Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa IBS Treatment Market Size (2018-2029)
2 IBS Treatment Market by Type
2.1 Introduction
2.1.1 IBS-D
2.1.2 IBS-C
2.1.3 IBS-M
2.2 Global IBS Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global IBS Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global IBS Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America IBS Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe IBS Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific IBS Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America IBS Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa IBS Treatment Revenue Breakdown by Type (2018-2029)
3 IBS Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Research Laboratories
3.2 Global IBS Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global IBS Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global IBS Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America IBS Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe IBS Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific IBS Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America IBS Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa IBS Treatment Revenue Breakdown by Application (2018-2029)
4 IBS Treatment Competition Analysis by Players
4.1 Global IBS Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in IBS Treatment as of 2022)
4.3 Date of Key Players Enter into IBS Treatment Market
4.4 Global Top Players IBS Treatment Headquarters and Area Served
4.5 Key Players IBS Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 IBS Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Allergan (Ireland)
5.1.1 Allergan (Ireland) Profile
5.1.2 Allergan (Ireland) Main Business
5.1.3 Allergan (Ireland) IBS Treatment Products, Services and Solutions
5.1.4 Allergan (Ireland) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Allergan (Ireland) Recent Developments
5.2 Sucampo Pharmaceuticals (U.S.)
5.2.1 Sucampo Pharmaceuticals (U.S.) Profile
5.2.2 Sucampo Pharmaceuticals (U.S.) Main Business
5.2.3 Sucampo Pharmaceuticals (U.S.) IBS Treatment Products, Services and Solutions
5.2.4 Sucampo Pharmaceuticals (U.S.) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Sucampo Pharmaceuticals (U.S.) Recent Developments
5.3 Ironwood Pharmaceuticals (U.S.)
5.3.1 Ironwood Pharmaceuticals (U.S.) Profile
5.3.2 Ironwood Pharmaceuticals (U.S.) Main Business
5.3.3 Ironwood Pharmaceuticals (U.S.) IBS Treatment Products, Services and Solutions
5.3.4 Ironwood Pharmaceuticals (U.S.) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Astellas Pharma (Japan) Recent Developments
5.4 Astellas Pharma (Japan)
5.4.1 Astellas Pharma (Japan) Profile
5.4.2 Astellas Pharma (Japan) Main Business
5.4.3 Astellas Pharma (Japan) IBS Treatment Products, Services and Solutions
5.4.4 Astellas Pharma (Japan) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Astellas Pharma (Japan) Recent Developments
5.5 Bausch Health
5.5.1 Bausch Health Profile
5.5.2 Bausch Health Main Business
5.5.3 Bausch Health IBS Treatment Products, Services and Solutions
5.5.4 Bausch Health IBS Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Bausch Health Recent Developments
5.6 Abbott Laboratories (U.S.)
5.6.1 Abbott Laboratories (U.S.) Profile
5.6.2 Abbott Laboratories (U.S.) Main Business
5.6.3 Abbott Laboratories (U.S.) IBS Treatment Products, Services and Solutions
5.6.4 Abbott Laboratories (U.S.) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Abbott Laboratories (U.S.) Recent Developments
5.7 Synergy Pharmaceuticals (U.S.)
5.7.1 Synergy Pharmaceuticals (U.S.) Profile
5.7.2 Synergy Pharmaceuticals (U.S.) Main Business
5.7.3 Synergy Pharmaceuticals (U.S.) IBS Treatment Products, Services and Solutions
5.7.4 Synergy Pharmaceuticals (U.S.) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Synergy Pharmaceuticals (U.S.) Recent Developments
5.8 Ardelyx (U.S.)
5.8.1 Ardelyx (U.S.) Profile
5.8.2 Ardelyx (U.S.) Main Business
5.8.3 Ardelyx (U.S.) IBS Treatment Products, Services and Solutions
5.8.4 Ardelyx (U.S.) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Ardelyx (U.S.) Recent Developments
5.9 Nestle (Switzerland)
5.9.1 Nestle (Switzerland) Profile
5.9.2 Nestle (Switzerland) Main Business
5.9.3 Nestle (Switzerland) IBS Treatment Products, Services and Solutions
5.9.4 Nestle (Switzerland) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Nestle (Switzerland) Recent Developments
5.10 Sebela Pharmaceuticals (Ireland)
5.10.1 Sebela Pharmaceuticals (Ireland) Profile
5.10.2 Sebela Pharmaceuticals (Ireland) Main Business
5.10.3 Sebela Pharmaceuticals (Ireland) IBS Treatment Products, Services and Solutions
5.10.4 Sebela Pharmaceuticals (Ireland) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Sebela Pharmaceuticals (Ireland) Recent Developments
5.11 Probi (Sweden)
5.11.1 Probi (Sweden) Profile
5.11.2 Probi (Sweden) Main Business
5.11.3 Probi (Sweden) IBS Treatment Products, Services and Solutions
5.11.4 Probi (Sweden) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.11.5 Probi (Sweden) Recent Developments
5.12 Alfasigma USA (Italy)
5.12.1 Alfasigma USA (Italy) Profile
5.12.2 Alfasigma USA (Italy) Main Business
5.12.3 Alfasigma USA (Italy) IBS Treatment Products, Services and Solutions
5.12.4 Alfasigma USA (Italy) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.12.5 Alfasigma USA (Italy) Recent Developments
5.13 RedHill Biopharma (Israel)
5.13.1 RedHill Biopharma (Israel) Profile
5.13.2 RedHill Biopharma (Israel) Main Business
5.13.3 RedHill Biopharma (Israel) IBS Treatment Products, Services and Solutions
5.13.4 RedHill Biopharma (Israel) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.13.5 RedHill Biopharma (Israel) Recent Developments
5.14 AstraZeneca (U.K)
5.14.1 AstraZeneca (U.K) Profile
5.14.2 AstraZeneca (U.K) Main Business
5.14.3 AstraZeneca (U.K) IBS Treatment Products, Services and Solutions
5.14.4 AstraZeneca (U.K) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.14.5 AstraZeneca (U.K) Recent Developments
5.15 Ipsen (France)
5.15.1 Ipsen (France) Profile
5.15.2 Ipsen (France) Main Business
5.15.3 Ipsen (France) IBS Treatment Products, Services and Solutions
5.15.4 Ipsen (France) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.15.5 Ipsen (France) Recent Developments
5.16 Novartis (Switzerland)
5.16.1 Novartis (Switzerland) Profile
5.16.2 Novartis (Switzerland) Main Business
5.16.3 Novartis (Switzerland) IBS Treatment Products, Services and Solutions
5.16.4 Novartis (Switzerland) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.16.5 Novartis (Switzerland) Recent Developments
5.17 Takeda Pharmaceutical Company (Japan)
5.17.1 Takeda Pharmaceutical Company (Japan) Profile
5.17.2 Takeda Pharmaceutical Company (Japan) Main Business
5.17.3 Takeda Pharmaceutical Company (Japan) IBS Treatment Products, Services and Solutions
5.17.4 Takeda Pharmaceutical Company (Japan) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.17.5 Takeda Pharmaceutical Company (Japan) Recent Developments
5.18 Synthetic Biologics (U.S.)
5.18.1 Synthetic Biologics (U.S.) Profile
5.18.2 Synthetic Biologics (U.S.) Main Business
5.18.3 Synthetic Biologics (U.S.) IBS Treatment Products, Services and Solutions
5.18.4 Synthetic Biologics (U.S.) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.18.5 Synthetic Biologics (U.S.) Recent Developments
5.19 Protagonist Therapeutics (U.S.)
5.19.1 Protagonist Therapeutics (U.S.) Profile
5.19.2 Protagonist Therapeutics (U.S.) Main Business
5.19.3 Protagonist Therapeutics (U.S.) IBS Treatment Products, Services and Solutions
5.19.4 Protagonist Therapeutics (U.S.) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.19.5 Protagonist Therapeutics (U.S.) Recent Developments
5.20 Pfizer (U.S.)
5.20.1 Pfizer (U.S.) Profile
5.20.2 Pfizer (U.S.) Main Business
5.20.3 Pfizer (U.S.) IBS Treatment Products, Services and Solutions
5.20.4 Pfizer (U.S.) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.20.5 Pfizer (U.S.) Recent Developments
5.21 Lexicon Pharmaceuticals (U.S.)
5.21.1 Lexicon Pharmaceuticals (U.S.) Profile
5.21.2 Lexicon Pharmaceuticals (U.S.) Main Business
5.21.3 Lexicon Pharmaceuticals (U.S.) IBS Treatment Products, Services and Solutions
5.21.4 Lexicon Pharmaceuticals (U.S.) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.21.5 Lexicon Pharmaceuticals (U.S.) Recent Developments
5.22 Innovate Biopharmaceuticals (U.S.)
5.22.1 Innovate Biopharmaceuticals (U.S.) Profile
5.22.2 Innovate Biopharmaceuticals (U.S.) Main Business
5.22.3 Innovate Biopharmaceuticals (U.S.) IBS Treatment Products, Services and Solutions
5.22.4 Innovate Biopharmaceuticals (U.S.) IBS Treatment Revenue (US$ Million) & (2018-2023)
5.22.5 Innovate Biopharmaceuticals (U.S.) Recent Developments
6 North America
6.1 North America IBS Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe IBS Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific IBS Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America IBS Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa IBS Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 IBS Treatment Market Dynamics
11.1 IBS Treatment Industry Trends
11.2 IBS Treatment Market Drivers
11.3 IBS Treatment Market Challenges
11.4 IBS Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
